Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adefovir dipivoxil + hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intramuscular
01
Overview
Adefovir dipivoxil is an orally administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for the treatment of chronic hepatitis B. It is a prodrug that is converted in vivo to adefovir and then phosphorylated to its active form, adefovir diphosphate. The active metabolite inhibits hepatitis B virus (HBV) DNA polymerase by competing with deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA. This results in decreased HBV replication[2][3][4]. Adefovir also has immunomodulatory effects and can improve T cell immune function in patients with chronic hepatitis B[6]. The drug was developed by Gilead and has been marketed under the brand name Hepsera[5]. The "hepatitis B vaccine" refers to recombinant protein vaccines that induce immunity against HBV infection by stimulating the production of protective antibodies against the surface antigen of HBV. This entry represents a combination of an antiviral small molecule (adefovir dipivoxil) and an immunoprophylactic biologic (hepatitis B vaccine), which are sometimes used sequentially or together for management or prevention strategies related to hepatitis B but are not available as a fixed-dose combination product.
- Other names
- adefovir di(pivaloyloxymethyl) esteradefovir pivoxil
02
Targets
HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on adefovir dipivoxil + hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adefovir dipivoxil + hepatitis B vaccine.